A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta (Aβ) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD. METHODS: The study enrolled 234 patients, randomly assigned to IV bap...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Salloway, S, Sperling, R, Gilman, S, Fox, N C., Blennow, K, Raskind, M, Sabbagh, M, Honig, L S., Doody, R, van Dyck, C H., Mulnard, R, Barakos, J, Gregg, K M., Liu, E, Lieberburg, I, Schenk, D, Black, R, Grundman, M
Format: Artigo
Idioma:Inglês
Publicat: American Academy of Neurology 2009
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2790221/
https://ncbi.nlm.nih.gov/pubmed/19923550
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e3181c67808
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars